These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3149210)

  • 1. Diurnal variation in pharmacokinetics of valproic acid with unequal dosing intervals.
    Johno I; Nakamura T; Horiuchi T; Nadai M; Kitazawa S; Yoshimine N; Kuzuya F
    Chem Pharm Bull (Tokyo); 1988 Jul; 36(7):2551-6. PubMed ID: 3149210
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronopharmacokinetics of valproic acid following constant-rate administration in mice and influence of feeding schedule.
    Song JG; Ohdo S; Ogawa N
    Zhongguo Yao Li Xue Bao; 1995 Mar; 16(2):113-7. PubMed ID: 7597908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian variation of Valproic acid pharmacokinetics in mice.
    Ben-Cherif W; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA
    Eur J Pharm Sci; 2013 Jul; 49(4):468-73. PubMed ID: 23707469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
    Dutta S; Reed RC; Cavanaugh JH
    Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronopharmacology and DDS (drug delivery system)].
    Ogawa N; Ohdo S
    Nihon Rinsho; 1993 Oct; 51(10):2778-87. PubMed ID: 8254954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs pharmacokinetics in ICU patients: consequences of hypoalbuminemia upon drugs monitoring and dosing scheme.
    Lagneau F; Perbet S; Delefosse D; Wernet A; Stocco J; Marty J
    Intensive Care Med; 2004 Jun; 30(6):1247. PubMed ID: 15138675
    [No Abstract]   [Full Text] [Related]  

  • 7. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers.
    Cawello W; Bonn R
    J Clin Pharmacol; 2012 Nov; 52(11):1739-48. PubMed ID: 22162508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detailed monitoring of valproic acid and phenobarbital in the treatment of epilepsy in children].
    Sobaniec W; Jankowicz E; Czerwińska-Ciechan K
    Neurol Neurochir Pol; 1988; 22(5):413-20. PubMed ID: 3150521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy testing of valproic acid compared to ethosuximide in monkey model: I. Dosage regimen design in the presence of diurnal oscillations.
    Levy RH; Lockard JS; Patel IH; Lai AA
    Epilepsia; 1977 Jun; 18(2):191-203. PubMed ID: 406138
    [No Abstract]   [Full Text] [Related]  

  • 10. [Inequality of bioavailability in commercial tablets of valproic acid].
    Koide N; Abe M
    No To Hattatsu; 1990 Sep; 22(5):516-7. PubMed ID: 2223193
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.
    Ragueneau-Majlessi I; Levy RH; Brodie M; Smith D; Shah J; Grundy JS
    Clin Pharmacokinet; 2005; 44(5):517-23. PubMed ID: 15871637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian variation in anticonvulsant activity of valproic acid in mice.
    Khedhaier WBC; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA
    Biomed Pharmacother; 2017 Nov; 95():25-30. PubMed ID: 28826093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.
    Miljković B; Pokrajac M; Varagić V; Lević Z
    Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time, in vivo monitoring and pharmacokinetics of valproic acid via a novel biomarker in exhaled breath.
    Gamez G; Zhu L; Disko A; Chen H; Azov V; Chingin K; Krämer G; Zenobi R
    Chem Commun (Camb); 2011 May; 47(17):4884-6. PubMed ID: 21373707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens.
    Methaneethorn J
    Clin Ther; 2017 Jun; 39(6):1171-1181. PubMed ID: 28483293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of felbamate on valproic acid disposition.
    Wagner ML; Graves NM; Leppik IE; Remmel RP; Shumaker RC; Ward DL; Perhach JL
    Clin Pharmacol Ther; 1994 Nov; 56(5):494-502. PubMed ID: 7955813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divalproex-ER pharmacokinetics in older children and adolescents.
    Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
    Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.
    Van Matre ET; Cook AM
    Neurol Res; 2016 Sep; 38(9):786-91. PubMed ID: 27414414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which oral valproic acid formulation is best for my patient?
    Knox JE; Freeland KN
    JAAPA; 2015 Jan; 28(1):21-3. PubMed ID: 25522023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.